Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OSCAR SOTO RAICES

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1962441717
CMS profile
179451
Location
SAN JUAN, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$64,103.22

115 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OSCAR SOTO RAICES

NPI 1962441717 · CMS profile ID 179451

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SAN JUAN, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962441717?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OSCAR SOTO RAICES, NPI 1962441717, CMS profile ID 179451. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962441717?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). OSCAR SOTO RAICES, NPI 1962441717, CMS profile ID 179451. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962441717?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
OSCAR SOTO RAICES, NPI 1962441717, CMS profile ID 179451, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1962441717?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

115 matching records · $64,103.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 115 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 115.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $25.0008/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939784641 CMS
Lilly USA, LLC $3,737.5007/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918259335 CMS
Lilly USA, LLC $25.2307/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918212395 CMS
Lilly USA, LLC $23.4907/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918218077 CMS
Lilly USA, LLC $50.0007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061281726 CMS
Lilly USA, LLC $45.0007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918217091 CMS
Lilly USA, LLC $215.6507/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918218071 CMS
Lilly USA, LLC $195.0007/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918218073 CMS
Lilly USA, LLC $35.0007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918244379 CMS
Lilly USA, LLC $1,242.6607/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918252181 CMS
Lilly USA, LLC $25.0007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918252183 CMS
Lilly USA, LLC $25.0007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918252185 CMS
Lilly USA, LLC $19.5007/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918259329 CMS
Lilly USA, LLC $13.6507/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918259331 CMS
Lilly USA, LLC $60.0007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918272799 CMS
Horizon Therapeutics plc $23.4407/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937700097 CMS
Horizon Therapeutics plc $22.7306/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937700095 CMS
ABBVIE INC. $1,200.0006/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645705 CMS
GlaxoSmithKline, LLC. $1,300.0005/24/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951890619 CMS
Lilly USA, LLC $875.0005/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918212393 CMS
Lilly USA, LLC $2,300.0005/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918217093 CMS
Eli Lilly Export S.A. Puerto Rico Branch $25.0005/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918189949 CMS
Organon LLC $20.0005/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946395113 CMS
ABBVIE INC. $69.3004/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645699 CMS
ABBVIE INC. $59.4804/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645701 CMS
ABBVIE INC. $25.6704/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645703 CMS
PBG PUERTO RICO LLC $3.3504/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949387195 CMS
PBG PUERTO RICO LLC $17.6004/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949104247 CMS
ABBVIE INC. $61.9204/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645697 CMS
Janssen Pharmaceuticals, Inc $20.4703/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886866645 CMS
ABBVIE INC. $3,200.0003/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645693 CMS
ABBVIE INC. $2,800.0003/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645695 CMS
E.R. Squibb & Sons, L.L.C. $23.5703/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932650607 CMS
ABBVIE INC. $12.8003/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645671 CMS
ABBVIE INC. $52.5303/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645673 CMS
ABBVIE INC. $12.7903/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645675 CMS
ABBVIE INC. $13.0703/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645677 CMS
ABBVIE INC. $12.8003/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645679 CMS
ABBVIE INC. $61.9603/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645681 CMS
ABBVIE INC. $11.5403/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645683 CMS
ABBVIE INC. $12.7903/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645685 CMS
ABBVIE INC. $78.7003/06/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645687 CMS
ABBVIE INC. $819.6003/06/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645689 CMS
ABBVIE INC. $8.6003/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645691 CMS
ABBVIE INC. $52.5303/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645647 CMS
ABBVIE INC. $11.6403/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645649 CMS
ABBVIE INC. $11.6303/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645651 CMS
ABBVIE INC. $11.6603/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645653 CMS
ABBVIE INC. $2.2303/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645655 CMS
ABBVIE INC. $11.6303/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891645657 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $140,344.32 236
PY2020 $45,353.22 102
PY2021 $22,169.74 53
PY2022 $64,103.22 115
PY2023 $35,862.34 82
PY2024 $34,738.75 80
PY2025 $9,352.13 52

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $488,727.77 48
PY2024 Recipient $4,476.16 4
PY2024 Principal investigator $228,165.71 18
PY2023 Recipient $1,318.98 1
PY2023 Principal investigator $447,961.20 48
PY2022 Recipient $5,959.00 6
PY2022 Principal investigator $375,337.28 60
PY2021 Recipient $5,686.64 3
PY2021 Principal investigator $421,779.52 51
PY2020 Recipient $1,212.50 3
PY2020 Principal investigator $367,777.09 90
PY2019 Recipient $11,079.99 6
PY2019 Principal investigator $458,790.79 32

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
MINDFUL RHEUMATIX
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202534633
Principal investigator 1 Janssen Research & Development, LLC $1,240.00 12/22/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175399820
Principal investigator 1 ABBVIE INC. $87.00 12/15/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202530498
Principal investigator 1 ABBVIE INC. $2,006.85 12/04/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202527358
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18.55 11/20/2025 Non-covered Recipient Entity
Mindful Medical Resarch
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235995681
Principal investigator 1 ABBVIE INC. $2,102.70 11/05/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522431
Principal investigator 1 ABBVIE INC. $2,372.17 11/04/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202520829
Principal investigator 1 ABBVIE INC. $6,541.91 10/09/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202513717
Principal investigator 1 Janssen Research & Development, LLC $3,157.50 09/29/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175399826
Principal investigator 1 ABBVIE INC. $2,000.00 09/24/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202512126
Principal investigator 1 ABBVIE INC. $250.00 09/23/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202511888
Principal investigator 1 ABBVIE INC. $1,000.00 09/05/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202510168
Principal investigator 1 ABBVIE INC. $1,965.00 09/04/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509228
Principal investigator 1 Janssen Research & Development, LLC $106.00 09/01/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175399832
Principal investigator 1 ABBVIE INC. $2,800.00 08/20/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202505239
Principal investigator 1 Janssen Research & Development, LLC $212.00 08/11/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175399800
Principal investigator 1 ABBVIE INC. $2,102.70 08/06/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202503181
Principal investigator 1 ABBVIE INC. $815.00 08/05/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501850
Principal investigator 1 ABBVIE INC. $753.80 08/05/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202501856
Principal investigator 1 ABBVIE INC. $8,000.00 07/28/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202500162
Principal investigator 1 ABBVIE INC. $337.50 07/08/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497162
Principal investigator 1 ABBVIE INC. $1,618.37 07/02/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202494865
Principal investigator 1 Eli Lilly and Company $640.24 06/09/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886118
Principal investigator 1 Janssen Research & Development, LLC $2,490.00 06/09/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175399814
Principal investigator 1 ABBVIE INC. $1,965.00 06/03/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202488133
Principal investigator 1 Janssen Research & Development, LLC $2,534.20 06/02/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175399778
Principal investigator 1 Janssen Research & Development, LLC $750.00 05/23/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175399783
Principal investigator 1 ABBVIE INC. $11,500.00 05/22/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202485935
Principal investigator 1 ABBVIE INC. $2,561.25 05/07/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483869
Principal investigator 1 ABBVIE INC. $3,280.87 05/06/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202482127
Principal investigator 1 ABBVIE INC. $70.00 05/06/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202482129
Principal investigator 1 ABBVIE INC. $250.00 04/24/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202479312
Principal investigator 1 ABBVIE INC. $4,675.44 04/03/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202473521
Principal investigator 1 Janssen Research & Development, LLC $3,263.50 03/31/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175399789
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $222,611.00 03/28/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187885334
Principal investigator 1 Janssen Research & Development, LLC $400.00 03/14/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175399806
Principal investigator 1 ABBVIE INC. $2,261.25 03/07/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202462027
Principal investigator 1 Janssen Research & Development, LLC $2,259.20 03/03/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175399794
Principal investigator 1 GlaxoSmithKline, LLC. $6,350.00 02/27/2025 Non-covered Recipient Entity
MINDFUL RHEUMATIX AND MEDICAL RESEARCH GROUP
THE EVALUATION OF USE OF BELIMUMAB IN ROUTINE CARE SETTINGS IN LUPUS N No dispute reported 06/30/2026 1192161584
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $14,255.00 02/24/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187886756
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $9,034.00 02/10/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884270
Principal investigator 1 Eli Lilly and Company $347.40 02/10/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187885026
Principal investigator 1 ABBVIE INC. $8,239.05 02/06/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202448337
Principal investigator 1 Eli Lilly and Company $4,880.52 01/27/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187884652
Principal investigator 1 Eli Lilly and Company $2,651.44 01/27/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187884654
Principal investigator 1 Janssen Research & Development, LLC $212.00 01/27/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175399772
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $131,651.00 01/21/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187886570
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $6,571.00 01/21/2025 Non-covered Recipient Entity
MINDFUL MEDICAL RESEARCH
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187886754